```
=> file hcaplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         2.31       2.31

FILE 'HCAPLUS' ENTERED AT 11:07:05 ON 22 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Feb 2008  VOL 148 ISS 9
FILE LAST UPDATED: 21 Feb 2008  (20080221/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s pneumococcus or (streptococcus pneumoniae)

          3474 PNEUMOCOCCUS
         52590 STREPTOCOCCUS
         29098 PNEUMONIAE
         11871 STREPTOCOCCUS PNEUMONIAE
                 (STREPTOCOCCUS(W)PNEUMONIAE)
L1       14371 PNEUMOCOCCUS OR (STREPTOCOCCUS PNEUMONIAE)

=> s type(w)(5 or V)

       1889913 TYPE
       6619816 5
       1140233 V
L2       14243 TYPE(W)(5 OR V)

=> s capsular

L3        7126 CAPSULAR

=> s vaccine or immunity or immunogenic

         67356 VACCINE
        104312 IMMUNITY
         16444 IMMUNOGENIC
L4      167370 VACCINE OR IMMUNITY OR IMMUNOGENIC

=> s l1 and l2

L5          26 L1 AND L2
```

```
=> s l1 and l2 and l3

L6           13 L1 AND L2 AND L3

=> s l1 and l2 and l4

L7            4 L1 AND L2 AND L4

=> s l1 and l2 and l3 and l4

L8            3 L1 AND L2 AND L3 AND L4

=> s l5 and (PY<2004 or AY<2004 or PRY<2004)

      23977297 PY<2004
       4762005 AY<2004
       4240576 PRY<2004
L9           25 L5 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l6 and (PY<2004 or AY<2004 or PRY<2004)

      23977297 PY<2004
       4762005 AY<2004
       4240576 PRY<2004
L10          13 L6 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l7 and (PY<2004 or AY<2004 or PRY<2004)

      23977297 PY<2004
       4762005 AY<2004
       4240576 PRY<2004
L11           4 L7 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s l8 and (PY<2004 or AY<2004 or PRY<2004)

      23977297 PY<2004
       4762005 AY<2004
       4240576 PRY<2004
L12           3 L8 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 2.69       5.00

FILE 'STNGUIDE' ENTERED AT 11:07:28 ON 22 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 15, 2008 (20080215/UP).

=> s l12 1-3 ti abs bib
MISSING OPERATOR L12 1-3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> y
Y IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
```

```
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l12 1-3 ti abs bib
MISSING OPERATOR L12 1-3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> y
Y IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> dl12 1-3 ti abs bib
DL12 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> dl 12 1-3 ti abs bib
DL IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> d l12 1-3 ti abs bib
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L12  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Carrier proteins for vaccines
AB   The disclosed invention provides improved carrier proteins for
     antigen-based vaccines, including polysaccharide-based vaccines.  An
     aspect of the invention employs tetanus toxin fragment C (TTc).  The
     inventors describe the preparation of recombinant TTc (rTTc) conjugates with
     meningococcal C, Y, and W polysaccharides (GCMP-rTTc, GYMP-rTTc, and
     GWMP-rTTc, resp.) and comparison with tetanus toxoid (TT) conjugates
     (GCMP-TT, GYMP-TT, and GWMP-TT, resp.).  Also presented is the preparation of
     group B streptococcal polysaccharide (serotypes Ia, III, and V) conjugates
     with both TT and rTTc and their comparison.  The preclin. evaluation of
     rTTc conjugates was done in Swiss Webster female mice, 4-6 wks old,
     immunized at days 0, 28, and 42 with polysaccharide conjugated to either
     TT or rTTc, and monitored for polysaccharide-specific IgG and serum
     bactericidal activity (SBA).
AN   2005:14248  HCAPLUS <<LOGINID::20080222>>
DN   142:92169
TI   Carrier proteins for vaccines
IN   Kim, John; Michon, Francis J.
PA   Baxter International Inc., USA; Baxter Healthcare S.A.
SO   PCT Int. Appl., 30 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND    DATE        APPLICATION NO.         DATE
     ------------------  ----    --------    ----------------------  --------
PI   WO 2005000346       A1      20050106    WO 2004-US20026         20040623 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
```

```
            CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
            GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    AU 2004251726        A1   20050106    AU 2004-251726          20040623 <--
    CA 2530363           A1   20050106    CA 2004-2530363         20040623 <--
    EP 1638601           A1   20060329    EP 2004-776921          20040623 <--
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
           IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
    BR 2004011854        A    20060829    BR 2004-11854           20040623 <--
    JP 2007524621        T    20070830    JP 2006-517551          20040623 <--
    MX 2005PA14016       A    20060317    MX 2005-PA14016         20051220 <--
    US 2007014812        A1   20070118    US 2006-562256          20060628 <--
PRAI US 2003-480409P     P    20030623  <--
    WO 2004-US20026      W    20040623
RE.CNT  6     THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12  ANSWER 2 OF 3  HCAPLUS  COPYRIGHT 2008 ACS on STN
TI   Serotyping and antimicrobial susceptibility of group B Streptococcus over
     an eight-year period in southern Taiwan
AB   The increase in penicillin resistance among pneumococci and viridans
     streptococci and the development of serotype-specific conjugate
     vaccine have increased the need for knowledge of the antimicrobial
     susceptibility and the capsular serotypes of group B
     streptococci.  Over an 8-yr period, 351 group B streptococcal isolates
     from southern Taiwan were tested for antimicrobial susceptibility and
     serotype determination  Eighty-seven percent of the isolates were typeable.
Types
     III (28.5%) and V (27.1%) were the most common serotypes.  The occurrence
     of type V isolates increased with age, while that of
     type III isolates decreased with age, showing a predominance in children
     less than 1 yr of age.  Of 118 isolates from cases of invasive infection,
     types Ia, Ib, II, III, IV, and V accounted for 12.7, 11.9, 0.8, 33, 1.7,
     and 26.3%, resp.  Using the agar dilution method, all isolates were found to
     be susceptible to penicillin, cefotaxime, and vancomycin, 99.4% to
     ofloxacin, 78.1% to chloramphenicol, 63.2% to azithromycin, 62.6% to
     erythromycin, 57.3% to clindamycin, and 2.8% to tetracycline.
     Chloramphenicol resistance was associated with type III isolates (59 of 100,
     59%) and erythromycin and azithromycin resistance with type Ib isolates
     (25 of 33 [76%], and 21 of 33 [64%], resp.).  Thus, 72% of the isolates
     from invasive infections were serotype III, V, or Ia, and penicillin
     remains the drug of choice for treatment or prophylaxis of group B
     streptococcal infections in southern Taiwan, despite the high prevalence
     of penicillin resistance among Streptococcus pneumoniae
     and viridans streptococci.
AN   2001:529218  HCAPLUS <<LOGINID::20080222>>
DN   135:269927
TI   Serotyping and antimicrobial susceptibility of group B Streptococcus over
     an eight-year period in southern Taiwan
AU   Ko, W. C.; Lee, H. C.; Wang, L. R.; Lee, C. T.; Liu, A. J.; Wu, J. J.
CS   Department of Medicine, National Cheng Kung University Medical College,
     Tainan, 701, Taiwan
SO   European Journal of Clinical Microbiology & Infectious Diseases (
     2001), 20(5), 334-339
```

CODEN: EJCDEU; ISSN: 0934-9723
PB Springer-Verlag
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN
TI Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy
AB The feasibility of preventing invasive pneumococcal infections during the first few months of life by immunization during pregnancy has been investigated. One hundred and fifty Gambian women were immunized with either a 23-valent pneumococcal polysaccharide vaccine or a meningococcal polysaccharide vaccine during the last trimester of pregnancy. Pregnant women showed a good antibody response to five of the six pneumococcal polysaccharides tested (types 1, 3, 5, 6, 14 and 19) but not to type 6 polysaccharide. Mean cord blood/maternal blood IgG antibody ratios varied from 24% (type 1) to 49% (type 3) and differed substantially between individual mother/infant pairs. Pneumococcal antibody levels were higher at birth in infants of women immunized with pneumococcal polysaccharide vaccine than in control infants. However, these antibodies disappeared rapidly during the first few months of life and it is uncertain how much clin. protection against pneumococcal infection maternal immunization would have provided.
AN 1996:585849 HCAPLUS <<LOGINID::20080222>>
DN 125:245106
TI Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy
AU O'Dempsey, T. J. D.; McArdle, T.; Ceesay, S. J.; Banya, W. A. S.; Demba, E.; Secka, O.; Leinonen, M.; Kayhty, H.; Francis, N.; Greenwood, B. M.
CS Medical Research Council Laboratories, Fajara, Gambia
SO Vaccine (1996), 14(10), 963-970
CODEN: VACCDE; ISSN: 0264-410X
PB Elsevier
DT Journal
LA English